News - Neurological

Filter

Current filters:

Neurological

Popular Filters

1 to 25 of 938 results

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

24-07-2014

US biotech firm Biogen Idec said that the European Commission has approved its subcutaneous injectable…

Biogen IdecCytokinesMultiple sclerosisNeurologicalPharmaceuticalPlegridyRegulationUSA

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

US court preliminary order to prevent Actavis launch of generic Gralise

US court preliminary order to prevent Actavis launch of generic Gralise

18-07-2014

Judge Joel Pisano of the US District Court for the District of New Jersey has entered an order preliminarily…

ActavisActavis Elizabeth LLCAnticonvulsantsDepomedGenericsGraliseHealth Medical PharmaLaw CrimeLegalNeurologicalPatentsPfizerUSA

Mylan wins motion to enjoin GSK from providing paroxetine CR to Apotex

Mylan wins motion to enjoin GSK from providing paroxetine CR to Apotex

17-07-2014

US generics drug major Mylan says that the US District Court for the District of New Jersey granted its…

ApotexGenericsGlaxoSmithKlineLegalMylanNeurologicalparoxetinePaxil-CRUSA

moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

moksha8 to commercialize BIAL’s eslicarbazepine in Brazil and Mexico

15-07-2014

Portuguese drugmaker BIAL and Brazil-based moksha8 have entered an exclusive license for the commercialization…

BIALBrazileslicarbazepineExaliefLicensingMexicoMoksha8NeurologicalPharmaceuticalPortugalZebinix

Targacept trial does not show superiority of TC-1734 over donepezil

Targacept trial does not show superiority of TC-1734 over donepezil

15-07-2014

US-based clinical-stage biopharma company Targacept has announced results from a Phase IIb monotherapy…

Alzheimer's diseaseDonepezilNeurologicalPharmaceuticalResearchTargaceptTC-1734USA

Janssen files to expand label for Invega Sustenna to show delayed time to relapse in schizophrenia

Janssen files to expand label for Invega Sustenna to show delayed time to relapse in schizophrenia

15-07-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has submitted a supplemental…

Invega SustennaJanssenNeurologicalPharmaceuticalRegulationSchizophreniaUSA

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

15-07-2014

Swiss pharma major Novartis has set up a collaboration with US not-for-profit group the Banner Alzheimer's…

Active immunotherapyAlzheimer's diseaseEuropeNeurologicalNovartisNovartis PharmaceuticalsPharmaceuticalResearchUSA

Canadian approval for Sunovion’s Aptiom

Canadian approval for Sunovion’s Aptiom

14-07-2014

USA-based drugmaker Sunovion Pharmaceuticals, a subsidiary of Japan’s Dainippon Sumitomo, has received…

AptiomBIA-2093-301CanadaDainippon Sumitomo PharmaEpilepsyNeurologicalPharmaceuticalRegulationSunovion Pharmaceuticals

Lundbeck and Otsuka file for US approval of brexpiprazole

Lundbeck and Otsuka file for US approval of brexpiprazole

14-07-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka have submitted a New Drug Application…

brexpiprazoleLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalPiperidinesRegulationUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

NICE issues positive draft FAD guidance on Tecfidera

NICE issues positive draft FAD guidance on Tecfidera

11-07-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued…

Biogen IdecBiotechnologyMultiple sclerosisNeurologicalPricingRegulationTecfideraUK

Research shows FDA approval process for ADHD drugs does not study long-term safety or efficacy

Research shows FDA approval process for ADHD drugs does not study long-term safety or efficacy

10-07-2014

Researchers have highlighted a flaw in the US Food and Drug Administration’s approval process for attention…

Kenneth MandlNeurologicalPharmaceuticalPharmacologyPharmacovigilanceRegulationRitalinUSA

UK’s NICE backs Lundbeck drug for alcohol dependence

UK’s NICE backs Lundbeck drug for alcohol dependence

10-07-2014

In new draft guidance, the UK drug watchdog the National Institute for Health and Care Excellence (NICE)…

LundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

Varenicline combined with nicotine patch improves smoking cessation rates

Varenicline combined with nicotine patch improves smoking cessation rates

09-07-2014

Combining the smoking cessation medication varenicline with nicotine replacement therapy was more effective…

ChantixNeurologicalNicotinePfizerPharmaceuticalResearchSmoking cessationUSAVarenicline

Acorda fights Actavis on generic of its multiple sclerosis drug Ampyra

Acorda fights Actavis on generic of its multiple sclerosis drug Ampyra

09-07-2014

Ireland-headquartered generics major Actavis has confirmed filing an Abbreviated New Drug Application…

Acorda TherapeuticsActavisAmpyradalfampridineGenericsLegalNeurologicalUSA

1 to 25 of 938 results

Back to top